Format

Send to

Choose Destination
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00055. Epub 2018 Jun 5.

Targeting the HGF/MET Axis Counters Primary Resistance to KIT Inhibition in KIT-Mutant Melanoma.

Author information

1
Junna Oba, Sun-Hee Kim, Wei-Lien Wang, Mariana P. Macedo, Fernando Carapeto, Meredith A McKean, John Van Arnam, Agda K. Eterovic, Shiraj Sen, Charuta R. Kale, Xiaoxing Yu, Cara L. Haymaker, Mark Routbort, Lauren E. Haydu, Chantale Bernatchez, Alexander J. Lazar, Elizabeth A. Grimm, David S. Hong, and Scott E. Woodman, The University of Texas MD Anderson Cancer Center, Houston, TX; and Mariana P. Macedo, AC Camargo Cancer Center, São Paulo, Brazil.
#
Contributed equally

Conflict of interest statement

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Junna Oba No relationship to disclose Sun-Hee Kim No relationship to disclose Wei-Lien Wang No relationship to disclose Mariana P. Macedo No relationship to disclose Fernando Carapeto No relationship to disclose Meredith A. McKean No relationship to disclose John Van Arnam No relationship to disclose Agda K. Eterovic No relationship to disclose Shiraj Sen No relationship to disclose Charuta R. Kale No relationship to disclose Xiaoxing Yu No relationship to disclose Cara L. Haymaker Research Funding: Nektar, Idera Mark Routbort No relationship to disclose Lauren E. Haydu No relationship to disclose Chantale Bernatchez Stock and Other Ownership Interests: Lexicon (I) Research Funding: Nektar, Idera, Iovance Biotherapeutics, MedImmune, Pfizer, EMD Serono Patents, Royalties, Other Intellectual Property: Patent pending on BTLA as a marker for better CD8 T cells for adoptive immunotherapy Alexander J. Lazar Employment: GE Healthcare (I) Leadership: Beta Cat Pharmaceuticals, Archer Biosciences Stock and Other Ownership Interests: Archer Biosciences, Beta Cat Pharmaceuticals Honoraria: Novartis, Bristol-Myers Squibb, Janssen Oncology, Roche Consulting or Advisory Role: Novartis, Illumina, GE Healthcare Research Funding: MedImmune, AstraZeneca, Roche, Novartis Patents, Royalties, Other Intellectual Property: Elsevier Travel, Accommodations, Expenses: Bristol-Myers Squibb, Novartis Elizabeth A. Grimm No relationship to disclose David S. Hong Stock and Other Ownership Interests: MolecularMatch, Oncorena Honoraria: Adaptimmune, Baxter, Merrimack, Bayer Consulting or Advisory Role: Baxter, Bayer, Guidepoint Global, Janssen Research Funding: Novartis, Genentech, Eisai, AstraZeneca, Pfizer, miRNA Therapeutics, Amgen, Daiichi Sankyo, Merck, Mirati Therapeutics, Eli Lilly, Adaptimmune, Abbvie, Bayer, Bristol-Myers Squibb, Genmab, Ignyta, Infinity Pharmaceuticals, Kite Pharma, Kyowa Hakko Kirin, Loxo, MedImmune, Molecular Templates, Takeda Travel, Accommodations, Expenses: Loxo, miRNA Therapeutics Other Relationship: Oncorena Scott E. Woodman No relationship to disclose

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center